Latest news and press releases about Crinetics Pharmaceuticals, Inc. (CRNX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist.
Price
| Price | $84.95 |
| Market Cap | $9.0B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 7.52 |
| EV / EBITDA | -17.68 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -44.22% |
| Return on Invested Capital | -43.98% |
| Return on Assets | -37.95% |
| Gross Margin | 99.16% |
| Operating Margin | -1302.52% |
| Net Margin | -1189.88% |
Related companies: ACAD · AKRO · DYN · IMVT · KYMR · NAMS · PRAX
Explore sector: Healthcare · Biotechnology
More sections of CRNX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks